MedTrace Logo

The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS

NCT02673632 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2016-02-04

No results posted yet for this study

Summary

The investigator suggests that PCOS women with high AMH levels are resistant to ovarian stimulation and may need adjustment of the dose of gonadotrophin.

Conditions

Interventions

DRUG

Merional ®

Using the long protocol of controlled ovarian hyperstimulation (COH). Down regulation by (Decapeptyl ®, Ferring) 0.1mg subcutaneously once daily starting from day 18 of the preceding cycle, human menopausal gonadotrophin (hMG) (Merional ®, IBSA) 75 IU starting from cycle day two after confirmation of down regulation (thin endometrium, number of follicular activity, E2 \< 50 pg/mL). hMG dose is optimized according to age, BMI, antral follicles count (AFC), the local protocol, FSH level and previous response. Usually PCO patients start by 150 IU.

Sponsors & Collaborators

  • Ain Shams Maternity Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-05-31
Completion
2016-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02673632 on ClinicalTrials.gov